A DNA Damage Response Related Signature to Predict Prognosis in Patients with Acute Myeloid Leukemia

Abstract

The prognosis of acute myeloid leukemia (AML) is disappointing in most subtypes and varies widely. DNA damage response (DDR) is associated with prognosis and immunotherapy in multiple cancers. Here, we identify a signature of eight DDR-related genes associated with overall survival, which stratifies AML patients into high- and low-risk groups. Patients in low-risk group were more likely to respond to sorafenib. The signature could be an independent prognostic predictor for patients treated with ADE and ADE plus gemtuzumab ozogamicin. Therefore, this DDR prognostic signature might be applied to prognostic stratification and treatment selection in AML patients, which warrants further studies.

Keywords:

• DNA damage response (DDR)
• ADE regimen
• gemtuzumab ozogamicin
• acute myeloid leukemia (AML)
• prognostic signature
• treatment selection

Authors’ contributions

HL, JW, JWu, YWa, YW, CJ and MZ were the principal authors in the conception and design of this study. XJ, XS, YZ, and SM analyzed the data and prepared the manuscript. GW, XZ, HLu, CX, WW, YH, LL, SC and HL critically revised the manuscript. All authors contributed to the article and approved the submitted version.

Disclosure statement

No potential conflict of interest was reported by the author(s).

Data availability statement

The datasets used and/or analyzed in this study are available in the TCGA (https://xenabrowser.net/datapages/), GEO databases (https://www.ncbi.nlm.nih.gov/gds), and TARGET database (https://target-data.nci.nih.gov/Public/AML/mRNA-seq).

Additional information

Funding

The project was supported by Sichuan Provincial People’s Hospital Foundation [No. 2021LY16], 2020 Sichuan Cadre Health Research Project [No. 2021-213], Natural Science Foundation of Sichuan Province [No. 23NFSC0607] and 2018 Entrepreneurial Leading Talent of Guangzhou Huangpu District and Guangzhou Development District [No. 2022-L023].